OligoclonalNanobodies -Conjugated Liposome-Coated PKH67 (Fluorescent dye) to Target Her2 in Breast Cancer

Breast cancer as the second most common cancer is considered a major problem among women. In 25 to 30 percent of breast cancers, amplification of the Her2 gene leads to the weak detection and aggressive behavior. So, Her2 receptor kinase used in the aim of treatment. Among the factors that targeted the Her receptor, tyrosine inhibitors and monoclonal antibodies have been attracted great attention. Trastuzumab is a humanized IgG1 monoclonal antibody against the extracellular domain of the HER2 receptorthat binds to domain IV of the extracellular segment of it. Despite significant applications, monoclonal antibodies have still limitations. A single-domain antibody (sdAb, called Nanobody) is an antibody fragment consisting of a single monomeric variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen.Nanobodies are the second generation of therapeutic agents that can be ideal because they show small molecules and monoclonal antibodies abilities together. Oligoclonal antibodies target the several epitopes of special antigen and seem to be much more effective than the single monoclonal antibodies. Liposomes are small artificial vesicles primarily composed of spherical shape that can be created from cholesterol and natural nontoxic phospholipids exhibiting amphiphilic properties. Th e conjugation of nanoparticles with antibodies combines the properties of the nanoparticles themselves with the specific and selective recognition ability of the antibodies to antigens. Antibody-based targeting is a promising approach in the development of targeted therapies for cancer. In this study Oligoclonal-Nanobodies conjugated liposome affinity to Her2 receptor compared with Herceptin (as FDA approved Her2 specific antibody) conjugated liposome affinity, using PKH67 fluorescent dye.

Breast cancer as the second most common cancer is considered a major problem among women. In 25 to 30 percent of breast cancers, amplification of the Her2 gene leads to the weak detection and aggressive behavior. So, Her2 receptor kinase used in the aim of treatment. Among the factors that targeted the Her receptor, tyrosine inhibitors and monoclonal antibodies have been attracted great attention. Trastuzumab is a humanized IgG1 monoclonal antibody against the extracellular domain of the HER2 receptorthat binds to domain IV of the extracellular segment of it. Despite significant applications, monoclonal antibodies have still limitations. A single-domain antibody (sdAb, called Nanobody) is an antibody fragment consisting of a single monomeric variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen.Nanobodies are the second generation of therapeutic agents that can be ideal because they show small molecules and monoclonal antibodies abilities together. Oligoclonal antibodies target the several epitopes of special antigen and seem to be much more effective than the single monoclonal antibodies. Liposomes are small artificial vesicles primarily composed of spherical shape that can be created from cholesterol and natural nontoxic phospholipids exhibiting amphiphilic properties. Th e conjugation of nanoparticles with antibodies combines the properties of the nanoparticles themselves with the specific and selective recognition ability of the antibodies to antigens. Antibody-based targeting is a promising approach in the development of targeted therapies for cancer. In this study Oligoclonal-Nanobodies conjugated liposome affinity to Her2 receptor compared with Herceptin (as FDA approved Her2 specific antibody) conjugated liposome affinity, using PKH67 fluorescent dye.